2025 HFM Symposium - Managing Hyperkalemia in Heart Failure: Implementing Strategies to Reduce Patient Risk
Jersey Desk/10300926

HAZLET, N.J. - JerseyDesk -- In this symposium, attendees will be provided with best practices by a multidisciplinary faculty on the prevention of hyperkalemia, identification of patients at risk for hyperkalemia, the importance of maintaining HF patients on RAASi's and preferably at target doses, recent clinical evidence with novel potassium binders, and strategies for effective communication with patients.

Click here for more information

CHAIR

Akshay Desai, MD, MPH
Professor of Medicine
Harvard Medical School
Cardiovascular Division
Brigham and Women's Hospital
Boston, Massachusetts

FACULTY

Nancy Albert, PhD, CCNS, CHFN, CCRN, NE-BC

More on Jersey Desk

• United States Congressional Candidate Peter Coe Verbica Unveils 25-Point Federal Plan to Help Make California Affordable Again
• D8Averse Launches D8Acapture: Disruptive Mobile-First App Transforms Utility Pole Data Collection
• Experience Trembling Firsthand with the New AgeMan® Tremor Simulator
• Mauro Schnaidman named as Managing Director in Miami, Florida
• Corner Property Management Appointed Managing Agent for Minneakoning Business Center in Flemington

Associate Chief Nursing Officer--Research and Innovation
Clinical Nurse Specialist--Kaufman Center for Heart Failure
Cleveland Clinic
Cleveland, Ohio

Stephen Greene, MD
Associate Professor of Medicine
Duke University School of Medicine
Duke Clinical Research Institute
Durham, North Carolina

Robert Page, PharmD, MSPH, BCPS, BCGP
Professor, Departments of Clinical Pharmacy and Physical Medicine
Skaggs School of Pharmacy and Pharmaceutical Sciences
CU Anschutz
Aurora, Colorado

Educational Objectives
- Identify HF patients at risk for hyperkalemia
- Explain the relationship between down-titration or discontinuation of RAASi therapy and clinical outcomes
- Describe the clinical profi les of novel potassium binders
- Interpret the evidence with novel potassium binders for lowering potassium levels and reducing the risk of down-titration of mineralocorticoid receptor antagonist (MRA) therapy

Target Audience
This educational activity is intended for clinicians who manage patients with heart failure.

More on Jersey Desk

• AT Information Products Expands U.S. Access to the Markoprint X1Jet Family of High-Performance Inkjet Printers
• Continued Streak of Recognitions with Multiple Chambers and Partners Rankings
• Anern Shines at SOLAR AFRICA Kenya with Solar Lithium Battery Storage Technology
• Last Call - Submit Your Proposal for the 2025 OpenSSL Conference in Prague
• Veritext Legal Solutions Participates in Spectrum360's Annual "A Walk for a Lifetime"

Educational Grant
Voxmedia International gratefully acknowledges the educational grant provided by AstraZeneca Pharmaceuticals.

Accreditation and Credit Designation Statements
Voxmedia, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Voxmedia, LLC designates this live activity for a maximum of 1.0 AMA PRA Category Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Nurse practitioners may participate in this educational activity and earn a certificate of completion as AANP accepts AMA PRA Category 1 Credits™ through its reciprocity agreements. The National Commission on Certification of Physician Assistants accepts AMA PRA Category 1 Credits™ from organizations accredited by the ACCME.